Heparin Therapeutics

Heparin Therapeutics is a clinical-stage biotechnology company focused on developing novel, non-anticoagulant heparin (NACH) derivatives for the treatment of inflammatory and hematologic disorders. The company's lead programs leverage the anti-inflammatory and selectin-inhibiting properties of heparin while removing its anticoagulant activity to avoid bleeding risks. Its primary focus is on treating vaso-occlusive crises in patients with sickle cell disease, where its lead candidate aims to reduce cell adhesion and improve blood flow. Heparin Therapeutics operates as a specialized developer of carbohydrate-based medicines targeting unmet needs in vascular and systemic inflammation.